景峰医药(000908) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥176,056,130.03, a decrease of 2.95% compared to ¥181,402,884.35 in the same period last year[3] - Net profit attributable to shareholders decreased by 61.69% to ¥1,278,629.96 from ¥3,338,005.22 year-on-year[3] - Basic and diluted earnings per share fell by 60.53% to ¥0.0015 from ¥0.0038 in the same period last year[3] - Net profit for Q1 2023 was CNY 8,743,250.95, a decline of 28.5% from CNY 12,166,960.10 in Q1 2022[15] - The company reported a decrease in basic and diluted earnings per share to CNY 0.0015 from CNY 0.0038 in the previous year[16] Cash Flow - The net cash flow from operating activities increased significantly by 295.27% to ¥13,623,933.97 compared to ¥3,446,754.01 in the previous year[3] - Cash flow from operating activities increased to CNY 202,370,713.36 in Q1 2023, compared to CNY 186,693,029.70 in Q1 2022, representing an increase of 8.9%[17] - The net cash flow from operating activities for Q1 2023 was ¥13,623,933.97, an increase from ¥3,446,754.01 in Q1 2022, representing a significant improvement[18] - Total cash inflow from operating activities amounted to ¥207,907,529.55, compared to ¥195,527,717.11 in the same period last year[18] - The company paid ¥30,851,865.05 in taxes during the quarter, compared to ¥8,052,906.25 in the previous year, reflecting increased tax obligations[18] - Cash received from other operating activities was ¥5,536,816.19, showing a decrease from ¥8,834,687.41 year-over-year[18] - The company incurred cash payments to employees totaling ¥36,266,206.23, a decrease from ¥39,982,668.05 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,474,206,115.16, reflecting a slight increase of 0.39% from ¥1,468,474,402.63 at the end of the previous year[3] - The company’s total assets amounted to CNY 1,474,206,115.16, a slight increase from CNY 1,468,474,402.63 at the end of the previous quarter[13] - Total liabilities were reported at CNY 1,251,235,538.73, a decrease from CNY 1,253,645,942.02 in the previous quarter[13] - The company’s equity attributable to shareholders increased to CNY 178,899,747.20 from CNY 177,927,696.16 in the previous quarter[13] Operating Costs and Income - Total operating costs for Q1 2023 were CNY 168,775,870.62, down from CNY 170,714,929.26 in the same period last year, reflecting a reduction of 1.1%[14] - The company reported a significant decrease in other income by 88.90%, primarily due to lower government subsidies compared to the previous year[6] Research and Development - Research and development expenditures capitalized increased by 30.14%, reflecting the company's commitment to innovation[6] - Research and development expenses for Q1 2023 were CNY 5,099,494.09, slightly up from CNY 4,875,944.05 in Q1 2022[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 73,540[7] Cash Flow from Investing and Financing Activities - The net cash flow from investing activities was -¥5,259,594.09, a decrease from ¥84,691,218.51 in Q1 2022, indicating a shift in investment strategy[19] - Cash inflow from financing activities totaled ¥138,000,000.00, while cash outflow was ¥147,210,453.05, resulting in a net cash flow of -¥9,210,453.05[19] - The company’s cash flow from financing activities included cash received from borrowings of ¥138,000,000.00, indicating reliance on debt financing[19] - The ending balance of cash and cash equivalents was ¥180,549,539.74, down from ¥151,688,057.20 in Q1 2022[19] - The company reported cash inflow from the disposal of fixed assets and other long-term assets of ¥1,129,800.00, compared to ¥900,800.00 in the previous year[18]